Physician

Reji John, MD

According to 2025 Medicare claims, Reji John, MD (NPI: 1245279421) practices nephrology in the Beaumont-Port Arthur, TX market, with the plurality of this provider's patient population coming from Jefferson, TX. This provider's primary affiliated billing organization is NECHES CLINIC PLLC (NPI: 1447629415; TIN: 474997152) and primary practice location at 77702-2225.

John's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 507 traditional Medicare patients, billed 2,959 HCPCS/CPT codes, and received $318,602 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 2,523 prescription claims across 407 beneficiaries totaling $771,192 in drug costs, led by Velphoro (Sucroferric Oxyhydroxide). DME data shows 33 claims. Open Payments data shows 5 records totaling $1,935. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $222,819 to $771,192. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $4,722 to $1,544.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	747	4,441	$381,672
2016	680	4,311	$355,754
2017	707	3,969	$359,592
2018	725	4,241	$399,079
2019	625	4,336	$437,818
2020	702	5,531	$480,817
2021	652	4,215	$482,524
2022	560	3,051	$354,994
2023	529	2,618	$330,396
2024	507	2,959	$318,602

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	264	2,085	$222,819
2016	246	1,866	$187,855
2017	255	1,851	$147,986
2018	262	1,891	$165,363
2019	253	2,061	$287,125
2020	267	1,938	$226,508
2021	269	1,738	$238,857
2022	324	1,944	$516,397
2023	368	2,078	$593,316
2024	407	2,523	$771,192

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	29	$2,214
2016	N/R	33	$1,557
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	50	$2,726
2020	N/R	25	$363
2021	N/R	N/R	N/R
2022	N/R	24	$1,788
2023	N/R	23	$1,544
2024	N/R	33	$21,569

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	88	474	$284
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	204	298	$97
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	90	212	$94
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	183	716	$63
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	225	351	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Velphoro	Sucroferric Oxyhydroxide	75	2,306	$244,584
Farxiga	Dapagliflozin Propanediol	211	9,759	$172,774
Xphozah	Tenapanor Hcl	28	840	$81,375
Jardiance	Empagliflozin	57	3,530	$66,158
Auryxia	Ferric Citrate	20	1,500	$54,041

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	N/R	14	$21,230
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	19	$339

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	4	$85	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$1,850	CSL Behring
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Reji John, MD?

Tedicare shows public-source Medicare data for Reji John, MD (NPI 1245279421), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Reji John, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Reji John, MD?

Reji John, MD is linked to NECHES CLINIC PLLC (billing NPI 1447629415) in the available physician profile data.

Does Reji John, MD have Open Payments data?

Reji John, MD has 5 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.